Obstructive Hypertrophic Cardiomyopathy
Conditions
Interventions
None listed
Sponsors
KINDAI University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with obstructive hypertrophic cardiomyopathy (HCM) Patients who meet the mavacamten administration criteria described in the 2025 revised Japanese Heart Failure Guidelines (those who continue to have NYHA functional class II-III symptoms despite pharmacological therapy with beta-blockers or calcium channel blockers) Patients with a left ventricular ejection fraction (LVEF) >=55% at rest Patients with a peak left ventricular outflow tract (LVOT) pressure gradient >=50 mmHg at rest, during Valsalva maneuver, or during exercise Patients who have received a sufficient explanation regarding the purpose and details of this study, have fully understood it, and have provided written informed consent of their own free will
Exclusion criteria
Exclusion criteria: Patients with a history of resuscitation after cardiac arrest Patients with a history of syncope, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) intervention within the past 6 months Patients who have undergone surgical septal myectomy or percutaneous transluminal septal myocardial ablation (PTSMA) within the past 6 months Patients with a history of hypersensitivity to mavacamten, severe hepatic impairment (Child-Pugh class C), or who are pregnant or possibly pregnant Patients who refuse to participate in the study or are deemed ineligible by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the change in the index of microcirculatory resistance (IMR) before and after 16 weeks of mavacamten treatment in patients with obstructive hypertrophic cardiomyopathy who have a peak left ventricular outflow tract pressure gradient 50 mmHg or higher and are in NYHA class 2 or higher. | — |
Countries
Japan
Contacts
Public ContactKoichiro Matsumura
KINDAI University Faculty of Medicine Cardiovascular Medicine
Outcome results
None listed